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Presented by R. L A N D G R A F 
Introduction 
Clinical and (especially) experimental studies indicate that the late complications of 
insulin-dependent diabetes are mainly due to derangements of glucose metabolism 
(Engerman et al, 1977; Pirart, 1978). It can therefore be assumed that early glucose 
normalization can prevent, arrest or even reverse vascular and neurological complica-
tions in diabetics (Cahill et al, 1976; Tchobroutsky, 1978; Irsigler et al, 1979; Viberti 
et al, 1979; Little, 1981; White et al, 1981,1982; Abouna et al, 1983; Lauritzen et al, 
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1983). Normoglycaemia cannot generally be achieved by conventional insulin ther-
apy, and it is obvious that new approaches to treatment, especially of type 1 diabetics, 
are required. One direction of development is concerned with artificial devices, such 
as implantable and non-implantable insulin delivery Systems with or without glucose 
sensor function (Pfeiffer et a l , 1974; Blackshear et a l , 1979; Peterson, 1982; Shichiri 
et a l , 1982). Another possibility exists in the transplantation of insulin-producing 
tissue, i.e. isolated islets or pancreas segments (Sutherland, 1981a, 1981b). 
The aims of pancreas transplantation in type 1 diabetes mellitus are to reduce the 
high morbidity and mortality (WHO, 1980), to improve psychosocial rehabilitation 
(Simmons et a l , 1980), and to normalize diabetic derangements of intermediary 
metabolism. End-stage renal failure is one of the major life-threatening complications 
for type 1 diabetics (McCrary et a l , 1981; Medical Service Study Group, 1981), and 
kidney transplantation has been performed quite often in these patients in recent 
years (Jervell et a l . , 1979; Najarian et a l , 1979). Since there are still many problems 
associated with pancreas transplantation, pancreas grafting has mostly been carried 
out in selected type 1 diabetics with end-stage renal failure together with kidney 
transplantation (Sutherland, 1981b, 1983). In recent years particularly, an increasing 
number of pancreas transplants have been successful, and glucose metabolism can be 
improved dramatically (Traeger et a l , 1981; Sutherland et a l . , 1982; Pozza et a l . , 
1983; Landgraf a l , 1984). 
In this study we will present clinical and functional data of 22 simultaneous kidney 
and pancreas transplants in 21 type 1 diabetics with end-stage renal failure. 
M a t e r i a l s a n d m e t h o d s 
P a t i e n t s 
Twenty-one type 1 diabetic patients with end-stage renal failure were accepted for 
treatment. Combined pancreatic and renal allotransplantation was performed in all 
patients, pancreatic retransplantation alone in one patient. The important clinical 
data for the patients are listed in Table 1. 
I n d i c a t i o n s f o r p a n c r e a s t r a n s p l a n t a t i o n 
The indications for simultaneous kidney and pancreas grafting so far accepted by our 
group are depicted in Table 2. Patients above the age of 50 years or those with severe 
vascular complications at a younger age were excluded. Blindness seems to increase 
the risk of pancreas transplantation because of difficulties in perioperative Co-
operation, and thus might be a relative contraindication. The usual preoperative 
check-up prior to transplantation was expanded by ultrasonography of the vascular 
System, radionuclide studies of the heart and, in most patients, coronary angiogra-
phy. 
D o n o r s e l e c t i o n 
Donor selection criteria and pancreatectomy have been described recently (Land et 
a l , 1984). 
D u c t o b l i t e r a t i o n 
The duct obliteration procedure was started immediately prior to transplantation; the 
duct was cannulated under hypothermic in-vitro conditions. Ethibloc® (= prolamine) 
was injected into the ductal System under x-ray control. Duct obliteration was 
considered to be efficient when the first signs of overinjection were noticed by x-ray 
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T a b l e 1 
C l i n i c a l d a t a o f t h e t y p e 1 d i a b e t i c s w i t h s i m u l t a n e o u s k i d n e y a n d p a n c r e a s t r a n s p l a n t a t i o n 
Patient Age/sex Duration Late complications 
number (years) of diabetes 
(years) Retinopathy 
grade 
Neuropathy 
severity 
Nephropathy' 
(months) 
Hypertension 
1 39/9 30 III + 12 H D + 
2 21/<J 19 III + + + 5 H D 
3 28/c? 26 II + + 24 H D + 
4 36/? 30 II 36 H D + 
5 4 I/o* 20 II + + 24 H D + 
6 33/9 20 II + 12 H D + 
7 26/0* 26 III + + + 12 H D + 
8 23 IIP + + 24 C A P D + 
9 25/9 16 IIP + + 24 H D + 
10 42/ö* 32 II + 7 C A P D + 
11 40/o* 31 II + 3 C A P D + 
12 33/9 25 II + + + 4 C A P D + 
13 27/9 18 II + + 9 H D + 
14 29 IIP + + 6 H D + 
15 33/<J 25 IIP + + 26 H D + 
16 43/9 15 II + + + 15 H D + 
17 32/9 23 II + + 4 C A P D + 
18 31/9 17 II + + 24 H D + 
19 38/c? 33 IIP + + 2 C A P D + 
20 40/o* 23 II + + 12 H D + 
21 35/9 25 II + 18 C A P D + 
H D = Haemodialysis; C A P D = Continuous ambulatory peritoneal dialysis; + Amaurosis. 
Females n= 10; males n = 11. Ranges: age 21-49 years (mean 34 years); duration of diabetes 15-33 years (mean 25 
years); duration of nephropathy 2-36 months (mean 15 months). 
T a b l e 2 
P a t i e n t s e l e c t i o n f o r p a n c r e a s t r a n s p l a n t a t i o n i n t y p e 1 d i a b e t e s m e l l i t u s 
Indications Rapidly progressive or end-stage renal failure 
Rapidly progressive proliferative retinopathy 
Brittie diabetes with unsuccessful insulin pump treatment 
Contraindications Age above 50 years 
Severe cerebral and/or cardiovascular complications 
Blindness (?) 
control. Following occlusion, the ductal orifice and all the parenehyma near the cut 
surface were ligated. 
R e c i p i e n t O p e r a t i o n 
We have recently modified our technique of pancreatic transplantation (Land et a l , 
1980). The segmental pancreas graft was situated in an upside-down position in the 
right iliac fossa by positioning the distal four-fifths intraperitoneally and one-fifth 
extraperitoneally. Circulation was established by end-to-side anastomosis of the 
portal vein to the right external iliac vein and of the coeliac axis (plus patch) to the 
right external iliac artery. Following closure of this wound, a renal graft from the 
same donor was placed in the left iliac fossa using the Standard technique. 
P o s t o p e r a t i v e m a n a g e m e n t 
Besides the common basic examinations of blood pressure, heart rate, body tem-
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perature, pulmonary gas exchange, acid-base balance and bowel function, the 
transplantation of two grafts requires a special monitoring of kidney and pancreas 
function. The pancreas transplant function monitoring consists of blood glucose 
determinations every 2 h during the first 2 days. Thereafter the intervals depend on 
organ function. In addition, C-peptide measurements were performed. The blocking 
effect of somatostatin on the exocrine function of the pancreas is controlled by daily 
determination of alpha-amylase in serum and transplant pancreatic fluid. Kidney 
transplant function is assessed by measuring urinary Output, urine osmolality, 
Creatinine clearance, and Creatinine and urea levels in the serum. In addition, fluid 
balance was monitored (Lenhart et a l , 1984). 
Immunosuppression consists of the administration of Cyclosporin A (CyA) and 
methylprednisolone (for further details see Table 3). For the hormonal blockade of 
the exocrine and endocrine pancreas transplant function, somatostatin was used— 
240 //g/h i.v. (Landgraf et a l , 1983). The endocrine B-cell function was suppressed by 
insulin administered intravenously by perfusor. In spite of total parenteral nutrition 
with carbohydrates (up to 3000 kcal/day), amino acids (70g/day) and fatty acids 
(500 kcal/day), we achieved normal blood glucose levels with this regimen. Oral 
nutrition was started as soon as possible depending on bowel function, which was 
significantly inhibited in some patients by somatostatin. To prevent venous thrombo-
sis in the transplanted organs, intravenous heparin was administered by perfusor in a 
dosage of 600-1200 i.u. to achieve a partial thromboplastin time of 60-80 s. In most 
cases perioperative antibiotic Prophylaxis with beta-lactams and aminoglycosides was 
extended for a period of about 6 days. 
T a b l e 3 
I m m u n o s u p p r e s s i v e p r o t o c o l 
Basic immunosuppression 
1. Cyclosporin i.v. 
Cyclosporin orally 
2. Glucocorticoids 
Methylprednisolone (MP) 
Antirejection therapy 
First rejection episode 
Second/third rejection episode 
3-5 mg/kg daily over 10 days postoperatively 
15 mg/kg-> 8-6 mg/kg over the next 5 months, then 
low-dose continuation 
500 mg i.v. intraoperatively 
250 mg-»30 mg daily over the first weeks postoperati-
vely, then reduction to 8 mg daily within 2 months 
postoperatively. Discontinuation after 6 months post-
operatively 
3 x M P :500 mg i.v. daily 
MP: 120 mg i.v. daily plus A T G (Fresenius) 4.5-7 mg/ 
kg daily over a period of 7 days 
F o l l o w - u p o f t h e p a t i e n t s 
The patients were trained in self-monitoring of blood pressure, body temperature, 
body weight, urine volume and blood glucose at least twice daily with a quantitative 
reflectometer System, and in recording of the data after discharge from the hospital. 
Intensive ambulatory check-ups at least every week for about 2 months and thereafter 
at 3- to 4-week intervals were performed. In addition, every 3-6 months neurological 
and ophthalmological investigations were carried out. 
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M e t h o d s 
After an overnight fast, oral glucose tolerance tests were performed with 100 g glucose 
as Dextro-OGT® (Boehringer Mannheim, F .R .G . ) every 3-6 months. To test the 
glucagon secretory capacity, a combined test with 100 g glucose orally, followed 2 h 
later by 500 ml arginine Solution (6 g/dl), infused over 30 min, was performed. Blood 
samples were collected at 0, 30, 60, 120 and 180 min during the oral glucose tolerance 
tests alone, and during the combined tests at 0, 30, 60, 120, 125, 130, 140, 150, and 
180 min. The following parameters were measured: blood glucose (glucose oxidase 
method), C-peptide as radioimmunoassay ( IRE Diagnostic G m b H , Frechen, 
F .R .G. ) , insulin (Haies and Rändle, 1983) and glucagon (Heding, 1971) using 
antiserum K 5563 from Novo Copenhagen, Denmark. Cyclosporin A was monitored 
by measuring whole blood levels using a radioimmunoassay of Sandoz, Basel, 
Switzerland, with some modifications. The therapeutic ränge for blood con-
centrations was considered to be between 250 ng/ml and 750 ng/ml. 
R e s u l t s 
G r a f t f u n c t i o n s 
Since patients 1 to 3 (see Table 1), treated with conventional immunosuppression 
(azathioprine and glucocorticoids), have already been discussed in detail elsewhere 
(Landgraf et a l , 1983), the results presented here are exclusively those for patients 
treated with C y A . Currently, from these 18 patients, 14 have functional renal grafts, 
resulting in a kidney transplant survival rate of 78%. Two of the kidneys were lost due 
to acute rejection and 2 patients died a few weeks after transplantation from acute 
liver insufficiency without functional grafts. This demonstrates that renal graft 
survival rate is not significantly different from that for kidney grafting alone 
(European Multicentre Trial Group, 1983), indicating that the simultaneous trans-
plantation of a pancreas segment plus kidney did not increase the risk of renal graft 
loss. 
Of the 19 pancreatic transplantations, 2 were lost due to venous thrombosis of the 
graft (patient 4), 2 grafts were acutely rejected, 2 were lost after graft infection and, as 
already mentioned, 2 patients died without functioning grafts. Eleven pancreatic 
transplants are currently functioning. The ränge of survival time of the pancreas 
grafts lies between 1 month and 31 months (Table 4). O f the 11 patients, 5 had an 
impaired glucose tolerance, 2 of them with elevated haemoglobin A , (HbAj) levels, 
T a b l e 4 
R e s u l t s o f s e g m e n t a l p a n c r e a t i c t r a n s p l a n t a t i o n i n C y A - t r e a t e d p a t i e n t s 
Total 19 (100) 
Graft losses Venous thrombosis 2 (10.5) 
Infection 
Rejection 
Patient death 
2 (10.5) 
2(10.5) 
2 (10.5) 
Functioning grafts 11(58) 
(31, 21, 12, 11, 10, 7, 5, 5, 2, 2, 1 months) 
Impaired glucose tolerance 
Normal glucose tolerance 
5(45) 
6(55) 
Figures in parentheses are percentages. 
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and 6 patients showed completely normal glucose tolerance by W H O criteria (WHO, 
1980), and normal HbAj values. 
The long-term individual follow-up of glucose tolerance tests should be able to 
answer the important question of whether duct occlusion-induced exocrine pancreas 
fibrosis also influences the endocrine part of the grafted gland. The functional data of 
the two diabetics with the longest pancreas graft survival are therefore depicted in 
Figs 1 and 2. Normal (Fig. 1) or impaired (Fig. 2) glucose utilization did not 
significantly alter during the Observation time, of 19 and 32 months respectively. Nor 
did insulin release decrease. The glucagon values were comparable during these 
19 Months 
60 120 180 o 
Minutes after glucose 
F i g . 1. B l o o d g l u c o s e , s e r u m i n s u l i n , C - p e p t i d e a n d p l a s m a g l u c a g o n d u r i n g o r a l g l u c o s e 
t o l e r a n c e t e s t s o r o r a l g l u c o s e ( 1 0 0 g ) p l u s a r g i n i n e i . v . ( s h a d e d a r e a ) 1 - 1 9 m o n t h s a f t e r 
t r a n s p l a n t a t i o n i n p a t i e n t n u m b e r 6. H b A 1 l e v e l s w e r e m e a s u r e d a t t h e t i m e s o f t e s t i n g . 
( S e e a l s o T a b l e 1.) 
Observation times and reacted normally after glucose administration, i.e. partial 
suppression. Stimulation of insulin, C-peptide and glucagon after arginine infusion 
was documented (shaded areas in the figures). This demonstrates normal regulatory 
behaviour of the endocrine part of the grafted pancreas. The increasing levels of C-
peptide of patient 5 (Fig. 2) are due to a slow progression of renal insufficiency with 
elevated Creatinine values, leading to a decrease of C-peptide clearance. 
After interruption of pancreas graft function with excessively high blood glucose 
values during an oral glucose load and very low values of insulin (Fig. 3) in patient 7, 
insulin dependency disappeared slowly after antirejection treatment, and only 
impaired glucose tolerance persisted 5 months later. H b A , levels were in the upper 
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Minutes after glucose 
F i g . 2 . B l o o d g l u c o s e , s e r u m i n s u l i n , C - p e p t i d e a n d p l a s m a g l u c a g o n d u r i n g g l u c o s e 
t o l e r a n c e t e s t s o r o r a l g l u c o s e ( 1 0 0 g ) p l u s a r g i n i n e i . v . ( s h a d e d a r e a ) 3 - 3 2 m o n t h s a f t e r 
t r a n s p l a n t a t i o n i n p a t i e n t n u m b e r 5. H b A 1 l e v e l s w e r e m e a s u r e d a t t h e t i m e s o f t e s t i n g . 
( S e e a l s o T a b l e 1.) 
normal limit (normal up to 8.0%). In this patient, glucose with or without arginine 
stimulated insulin and glucagon release markedly. 
D i a b e t i c c o m p l i c a t i o n s 
R e t i n o p a t h y . Preproliferative and proliferative retinopathy was documented in all 
patients. Five patients were blind prior to transplantation. During strict anti-
coagulation immediately postoperatively and up to 6 weeks after transplantation, no 
significant deterioration of vision occurred in those patients who were not already 
blind. The follow-up of the 4 patients with the longest pancreatic survival time is 
summarized in Table 5. In all patients, the visual acuity did not decrease during the 
time of Observation. In patient 5, the visual acuity of the right eye was very low (light 
perception) prior to transplantation; about 18 months after successful trans-
plantation, vitrectomy of this eye was performed, but without success. During these 
18 months the visual acuity of the left eye improved significantly and fundoscopy 
demonstrated stabilization of retinopathy and disappearance of cotton-wool exu-
dates. However, about 20 months after transplantation, the first signs of preprolifera-
tive retinopathy (PPDR) existed and peripapillary proliferative retinal changes could 
be documented which stabilized after the initiation of laser coagulation therapy. 
Patient 6 had P P D R prior to transplantation. After complete normalization of renal 
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Minutes after glucose 
F i g . 3 . B l o o d g l u c o s e , s e r u m i n s u l i n , C - p e p t i d e a n d p l a s m a g l u c a g o n d u r i n g g l u c o s e 
t o l e r a n c e t e s t s o r o r a l g l u c o s e ( 1 0 0 g ) p l u s a r g i n i n e i . v . ( s h a d e d a r e a ) 3 , 8 a n d 11 m o n t h s 
a f t e r t r a n s p l a n t a t i o n a n d a f t e r a n t i r e j e c t i o n t r e a t m e n t i m m e d i a t e l y a f t e r t h e f i r s t t e s t a t 3 
m o n t h s i n p a t i e n t n u m b e r 7. ( S e e a l s o T a b l e 1.) 
function, glucose metabolism and disappearance of hypertension, P P D R improved 
and a mild and stable background retinopathy could be seen. In patient 7, who had 
proliferative retinopathy (PDR) with an almost complete loss of visual function prior 
to transplantation, not only did visual acuity improve but, more importantly, macula 
oedema decreased significantly. The P P D R of patient 10 stabilized and the number of 
cotton-wool exudates decreased markedly after successful transplantation of both 
pancreas and kidney. 
P e r i p h e r a l n e u r o p a t h y . In most patients the time after successful transplantation 
is too short to enable objective verification of change in diabetic neuropathy. 
However, in 6 patients who had severe subjective peripheral neuropathy, Symptoms 
such as burning sensations, hyperaesthesia and paraesthesia disappeared within 3 
months after successful pancreatic grafting. So far, it has been possible to follow-up 4 
patients in more detail (Fig. 4). Patient 10 had no subjective or objective signs of 
peripheral neuropathy immediately after transplantation, and did not show any 
change during the subsequent year. Patient 6 suffered from moderate neuropathy 
with decreased ankle jerks and loss of Vibration sense in both feet. While motor nerve 
conduction velocity remained normal, the sensory nerve conduction velocity 
increased within 21 months after grafting (Fig. 4). Two of the patients (5 and 12) had 
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T a b l e 5 
O p h t h a l m o l o g i c a l f o l l o w - u p a f t e r s u c c e s s f u l p a n c r e a t i c t r a n s p l a n t a t i o n 
Patient Prior After transplantation Comments 
number transplantation (months) 
1981 3 8 20 26 31 
5 OD 0 0 0 0 0 0 PPDR to mild 
OS 0.2 0.3 0.5 0.5 0.5 0.5 PDR under 
PPDR PPDR PPDR PDR PDR PDR control 
Cotton wool peri- slow progression 
Cotton wool papillär 
6 1974 1976 1981 6 14 21 
OD 0.8 1.0 1.0 1.0 0.8 0.8 Mild and stable 
OS 0.1 0.8 0.4 0.5 0.5 0.5 BDR 
PPDR BDR BDR BDR 
1981 11 
7 OD 0.05 0.1 No progression 
OS 0.03 blecding of PDR 
PDR macula 
oedema J, 
cotton wool PDR 
1981 4 10 
10 OD 0.8 0.8 0.8 Stable PPDR 
OS 0.6 0.6 0.6 
PPDR PPDR PPDR 
cotton wool cotton wool l 
BDR = background diabetic retinopathy, PPDR = preproliferative diabetic retinopathy, PDR = prolifer-
ative diabetic retinopathy, OD = right eye, OS = left eye. 
Numbers are the visual acuities. 
severe neuropathy with distal sensory loss of all modalities, compiete or incomplete 
loss of tendon reflexes, and severe motor dysfunctions. These signs were accompanied 
by autonomic nerve involvement such as severe postural hypotension. After trans-
plantation, subjective and objective signs of peripheral and autonomic neuropathy 
decreased and motor nerve conduction velocity (nervus peronaeus) improved (Fig. 4). 
D i s c u s s i o n 
T e c h n i q u e 
Our technique of combined segmental pancreatic and renal grafting using C y A as an 
immunosuppressant is a relatively safe procedure. However, the mortality rate, of 
around 10%, has to be taken into account when patients are counselled for 
transplantation, but all the patients in our study were already extremely III as a result 
of their severe diabetic Syndrome. Therefore, mortality could be reduced by earlier 
transplantation before the onset of the uraemic State of the disease. In addition, a 
strict selection of donors and recipients and improvement in the management of the 
patients, together with the opportunity for the transplant team to gain experience, 
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Patient 
number 
10 
12 
First examination 
Tendon Motor sensory 
reflexes Symptoms 
+ ++ +++ 
+ ++ 
N. peronaeus 
N. suralis 
Months after transplantation 
F i g . 4 . N e u r o l o g i c a l f o l l o w - u p i n p a t i e n t s n u m b e r 5, 6, 1 0 a n d 1 2 . N e u r o l o g i c a l e x a m i n a -
t i o n r e v e a l e d n o r m a l t e n d o n r e f l e x e s ( + + + ) i n p a t i e n t 1 0 a n d n o m o t o r o r s e n s o r y n e r v e 
S y m p t o m s ( - ) . C o n v e r s e l y , p a t i e n t 5 s h o w e d a c o m p l e t e a r e f l e x i a (-) a n d s e v e r e 
Symptoms o f p e r i p h e r a l n e u r o p a t h y ( + + + ) . M o t o r n e r v e ( n e r v u s p e r o n a e u s ) a n d s e n s o r y 
n e r v e ( n e r v u s s u r a l i s ) c o n d u c t i o n v e l o c i t i e s w e r e m e a s u r e d a t t i m e i n t e r v a l s d e p i c t e d i n t h e 
f i g u r e . ( S e e a l s o T a b l e 1.) 
play an important role in increasing the positive outcome of transplantation in 
diabetics. We assume that the relatively high rate of functioning pancreatic grafts is 
primarily due to the strong immunosuppressive potency of the new agent, cyclosporin 
A , which reduces the occurrence of irreversible allograft rejection. This is in 
accordance with the results in cadaveric renal transplantations, using C y A as 
immunosuppressive therapy (European Multicentre Trial Group, 1983). 
The morbidity observed in our patients following combined transplantation is 
certainly higher than that following kidney transplants. This morbidity mainly 
concerns the incidence of early local complications, such as peripancreatic fluid 
collection, transient pancreatic fistula at the site of the pancreatic graft with and 
without secondary infection, and severe wound haematomas at the site of the renal 
graft. The incidence of complications due to the residual function of the exocrine 
System of the duct-occluded pancreatic graft is particularly worrying. These local 
complications probably arise from a too early reabsorption of the occlusive substance 
(Ethibloc®) before the acini are completely atrophied (for a comparison of the effects 
of Ethibloc® and Neoprene, as used by the Lyon group, see Dubernard et a l . , 1983). It 
is worth mentioning that the administration of somatostatin intra- and postoperati-
vely did not prevent these complications arising from residual exocrine secretion. On 
the other hand, the property of early reabsorption of Ethibloc® may be the reason for 
the good long-term function of the pancreatic grafts because of its milder fibrosis-
inducing effect (Gebhardt and Stolte, 1978). 
G l u c o s e m e t a b o l i s m 
Half of the patients with functioning pancreatic grafts (i.e. insulin-independency) 
showed normal glucose disposal. This Observation is supported by others (Ostmann 
et a l . , 1980; Sutherland et a l , 1982; Pozza et a l , 1983; Landgraf et a l , 1984). The 
reasons for abnormal glucose disposal in the other half of the patients are certainly 
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complex and include denervation of the pancreas, and drainage of the islet hormones 
into the main circulation and not into the portal vein. Furthermore, only a part of the 
organ is transplanted, which might in addition be disturbed by circulatory and 
immunological mechanisms induced by duct-occlusion and allogenic transplantation. 
Most of the patients received glucocorticoids in addition to C y A , which will certainly 
contribute to impaired glucose tolerance. The possibility that C y A itself also leads to 
further deterioration of glucose utilization cannot be ruled out (Gunnarsson et a l . , 
1983b). 
The monitoring of pancreatic graft survival must be based primarily on blood 
glucose monitoring. However, hypoglycaemia might be a sign of irreversible damage 
of most of the endocrine tissue in the graft. Therefore measurements of direct 
Parameters of the transplanted islet tissue are urgently needed; determination of C-
peptide might provide this information (Gunnarson et a l . , 1983a). But as the C-
peptide assay is time consuming, it cannot be considered as very useful. Other 
candidates for use in the determination of early islet cell damage might be pancreatic 
Polypeptide or gamma enolase (Lindsey et a l , 1983), but again these assays, if 
available, are time consuming. Radiolabelled platelets seem to accumulate in the graft 
soon after initiation of rejection and have been used for the early detection of this 
process (Jurewicz et a l , 1984; Sollinger et a l . , 1984), but wide-ranging experience has 
not yet been gained. In combined transplantation of kidney and pancreas from the 
same donor, a rise in serum Creatinine and a decrease in Creatinine clearance seem to 
be the earliest signs of allograft rejection. 
Analysing glucose-induced insulin release in patients with functioning pancreatic 
grafts revealed patients with a normal secretory pattern, with excessively high or with 
subnormal values. In most patients, insulin release was delayed and maximal values 
were reached approximately 120 min after glucose load. In the transplanted patients 
receiving C y A , renal function was generally not completely normal, which may lead 
to changes in peripheral insulin sensitivity and in insulin clearance. In addition, most 
of our patients received glucocorticoids, which are known to reduce peripheral insulin 
responsiveness. Due to this complexity, glucose- and arginine-induced insulin and C-
peptide secretion are not markers solely for pancreatic graft function, but in addition 
reflect peripheral insulin sensitivity and insulin and C-peptide clearance. The data for 
glucagon release are even more difficult to interpret since, in addition to what has 
been discussed for insulin and C-peptide, glucagon in the peripheral blood is derived 
from the grafted pancreas as well as from the endogenous pancreas. However, since 
A-cell function is often impaired in type 1 diabetics (Unger and Orci, 1981a, 1981b), 
and since glucagon is an important glucoregulatory hormone, normal glucagon 
secretory behaviour, for example glucose-induced suppression and arginine-induced 
Stimulation, is an indicator for normalization of intermediary metabolism. 
L a t e d i a b e t i c c o m p l i c a t i o n s 
One of the important aims of pancreas transplantation is to prevent, arrest or even 
reverse late diabetic complications by normalization of the diabetic derangements of 
intermediary metabolism. The close follow-up of diabetic retinopathy and neuro-
pathy in pancreas-transplanted patients should answer some of the questions 
concerned with late complications and diabetic metabolism. The worldwide exper-
ience with pancreas transplantation and the number of patients with long-term 
survival of their pancreatic grafts are currently insufficient to enable definite 
conclusions to be drawn (Sutherland, 1984). However, diabetic neuropathy seems to 
be very sensitive to the degree of hyperglycaemia. Normalization of blood glucose 
with insulin pumps has led to improvements of diabetic neuropathy (Pietri et a l . , 
1980). The neurological follow-up of our patients with long-term functioning grafts 
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also revealed significant improvements of the severe neuropathy which had disabled 
most of them. Since combined pancreas and kidney grafting was performed in our 
patients, the positive changes in neuropathy are certainly a combined effect of the 
improvement or normalization of glucose metabolism and the disappearance of end-
stage renal failure. The documentation of changes in diabetic retinopathy after 
glucose normalization is even more difficult. This is due to the problems of defining 
qualitatively and quantitatively the exact degree of ocular changes in diabetics and 
the complexity of the causes inducing functional and morphological changes of the 
vascular System of the eyes. End-stage renal failure and high blood pressure add to the 
diabetic retinopathy, and eliminating one of these factors might improve the ocular 
function. The study of Pirart (1978) and the prospective study of the Steno Memorial 
Hospital (Lauritzen et a l . , 1983) have demonstrated that good blood glucose control 
might positively influence the degree and progression of diabetic retinopathy. In our 
patients with longer functioning pancreatic grafts, improvement or at least stabiliza-
tion of diabetic retinopathy could be documented, although in one patient a further 
progression was observed. 
Although comprehensive data are not yet available, studies to date indicate that it 
is not possible to define a point of 'no return' for patients suffering from the severe 
late complications of diabetes, and therefore the use of intensive therapeutic 
approaches, even when the disease has reached an advanced stage, is justified. 
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